Annual Meeting SVGO/ASCO and SBMS 2023

9. June 2023, Kursaal Allegro

| Registration |
|---|
| Welcome from SVGO and SBMS Presidents in «Aare» Meeting room |
| "State of the Art"- Basic Cellular players of human bone remodeling under physiological and pathophysiological conditions T.L. Andersen (Denmark) |
| Short communications 1 (4 selected abstracts). Chair: Pr. K. Lippuner |
| $09.50 - 10.00$: Late diagnosis of childhood-onset hypophosphatasia in an adult with recurrent fractures: the impact of enzyme replacement therapy. M . $Messikommer\ et\ al$. |
| 10.00 - 10.10: A dietary plus exercise intervention improves bone turnover in patients with metabolic syndrome and type 2 diabetes. <i>M. Gerbaix et al.</i> |
| 10.10 - 10.20: Muscle parameters in fragility fracture risk prediction in older adults: a scoping review. C. Vendrami et al. |
| 10.20 – 10.30: Effect of vitamin D3, omega-3s and a simple home exercise program on BMD in European older adults: preliminary findings from the DO-HEALTH randomized controlled trial. <i>M. Kistler-Fischbacher et al.</i> |
| Coffee Pause in "Aare Foyer" |
| Short communications 2 (4 selected abstracts). Chair: Pr. O. Lamy |
| 11.00 - 11.10: Hip fracture and refracture rate in subjects with an incident hip fracture at the Geneva University Hospital: a retrospective analysis. <i>I. Padlina et al.</i> |
| 11.10-11.20: Improving fracture prediction in patients with osteoporosis using machine learning techniques: a nationwide, registry-based cohort study. <i>J. Everts-Graber et al.</i> |
| 11.20 - 11.30: Assessment of total and bioactive serum sclerostin levels and its association with bone metabolism in type 2 diabetes mellitus. <i>C. Traechslin et al.</i> |
| 11.30 - 11.40: Ischemic stroke is associated with reduced sclerostin expression in human atherosclerotic plaques. F . Burger et al. |
| "State of the Art"- Translationnal. Chair: Pr. S. Ferrari Osteoporosis and CVD: Common mechanisms and impact of OP drugs on arterial calcifications S. Papapoulos (Greece) |
| Lunch in "Aare" Foyer |
| 3.30: SGBond members only: Voting of the new committee in "Aare" Meeting room) |
| ASCO/SVGO Symposium 1: MANAGEMENT OF VERTEBRAL FRACTURES. Chair: Pr. C. Meier |
| Neurosurgical guidelines D. Bellut (Zurich) |
| Osteoporosis treatments S. Ferrari (Geneva) |
| ASCO/SVGO Symposium 2: MANAGEMENT OF FRACTURE RISK IN CANCER PATIENTS. Chair: Dr. E. Biver |
| |

14.20 MGUS: Does it increase fracture risk and how to prevent it? R. Schmidmaier (Germany)



The Swiss Bone and Mineral Society

| 14.45 | Fracture prevention in hormone-ablative therapy for breast and prostate cancer Ch. Meier (Basel) |
|-------|---|
| 15.10 | BPs or denosumab for the prevention of SRE in advanced cancer E. Biver (Geneva) |
| 15.35 | Coffee Pause in "Aare Foyer" |
| | ASCO/SVGO/SG BOND symposium: THERAPEUTIC MANAGEMENT OF RARE BONE DISEASES (in "Aare" Meeting room). Chair: Pr. A. Trombetti |
| 16.00 | SGBond and Reference Centers for Rare Bone Diseases : our mission B. Aubry-Rozier (Lausanne) |
| 16.10 | Is there a place for burosumab in fibrous dysplasia? E. Gonzalez Rodriguez (Lausanne) |
| 16.35 | Bone manifestations of the different type of EDS M. Rohrbach (Zurich) |
| 16.50 | Awards ceremony |
| 17.00 | End of Meeting |
| 17.10 | SVGO: General Assembly |
| 18.00 | Adjourn |

13.30 - 16.30: PARRALEL PROGRAMM SBMS «Gaarten 2» Meeting room